Search results for "vaccine effectiveness"

showing 5 items of 5 documents

Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy

2019

Background: Influenza vaccines are updated every year to match the vaccine strains with currently circulating viruses; consequently influenza vaccine effectiveness (IVE) has to be assessed annually.Research design and methods: A test-negative case-control study was conducted within the context of the Italian sentinel influenza surveillance network to estimate IVE by age group, virus subtype, and vaccine brand in medically attended laboratory-confirmed influenza.Results: In Italy, the 2018/19 influenza season was characterized by the co-circulation of influenza A(H1N1)pdm09 and A(H3N2) viruses. The adjusted IVE estimate in preventing influenza was moderate (44.8%, 95% CI: 18.8 to 62.5) again…

Maletest-negative case-control study0301 basic medicinePrevalenceInfluenza vaccine effectiveness test-negative case-control study national influenza surveillance network ItalySettore MED/42 - Igiene Generale E ApplicataInfluenza A Virus H1N1 Subtype0302 clinical medicineDrug DiscoveryEpidemiology030212 general & internal medicineChildInfluenza vaccine effectivenessAged 80 and overnational influenza surveillance networkAge Factorsvirus diseasesMiddle Aged3. Good healthVaccinationTreatment OutcomeItalyInfluenza VaccinesChild PreschoolMolecular MedicineFemaleInfluenza vaccine effectiveness; Italy; national influenza surveillance network; test-negative case-control studyAdultmedicine.medical_specialtyAdolescentInfluenza vaccineImmunologyContext (language use)VirusYoung Adult03 medical and health sciencesInternal medicineInfluenza HumanmedicineAnimalsHumansAgedPharmacologybusiness.industryInfluenza A Virus H3N2 SubtypeCase-control studyInfant030104 developmental biologyImmunizationCase-Control StudiesbusinessExpert Review of Vaccines
researchProduct

Evaluation of the Burden of HPV-Related Hospitalizations as a Useful Tool to Increase Awareness: 2007–2017 Data from the Sicilian Hospital Discharge …

2020

In light of the implementation of human papillomavirus (HPV) prevention strategies, epidemiological studies in different geographical areas are required in order to assess the impact of HPV-related diseases. The purpose of the present study was to describe the burden of HPV-related hospitalizations in Sicily. A retrospective observational study estimated 43,531 hospitalizations attributable to HPV from 2007 to 2017. During the observed period, there was a decrease for all HPV-related conditions with a higher reduction, among neoplasms, for cervical cancer (annual percent change (APC) = &minus

medicine.medical_specialtycervical cancerImmunologyimpact evaluationcervical cancer screeninglcsh:MedicineCervical cancer screeningArticleburdenscreening effectiveness03 medical and health sciences0302 clinical medicineInternal medicineDrug DiscoveryCervical carcinomaEpidemiologyHospital dischargeScreening effectiveneMedicinePharmacology (medical)030212 general & internal medicineHPV vaccinePharmacologyCervical cancerHPV-related diseasevaccine effectivenessbusiness.industrylcsh:Rvirus diseasesRetrospective cohort studymedicine.diseaseVaccine introductionhospitalization rateAnnual Percent Changefemale genital diseases and pregnancy complicationsInfectious DiseasesItaly030220 oncology & carcinogenesisbusinessVaccines
researchProduct

Vaccination and Vaccine Effectiveness: A Commentary of Special Issue Editors

2020

The Special Issue “Vaccination and Vaccine Effectiveness”, published in the journal Vaccines, has the main aim to increase international literature data on vaccine effectiveness and safety and on vaccination strategies in order to reduce vaccine hesitancy and improve vaccination coverage rates. The main topics included in the call for papers were vaccines administered to infants, adolescents, adults, elderly people, at-risk populations (due to comorbidities and personal risk factors) and healthcare workers and strategies adopted to promote vaccination adherence among these categories. This Special Issue started from the assumption that, despite vaccination being universally recognized as on…

0301 basic medicinemedicine.medical_specialtyImmunologyPopulationlcsh:MedicineRubella and varicella vaccinationVaccines AdministeredMeasles03 medical and health sciences0302 clinical medicineQuality of life (healthcare)Internationally adopted childrenDrug DiscoveryHealth caremedicinemeaslesElderly peoplePharmacology (medical)Research article030212 general & internal medicinehepatitis B vaccinationeducationPharmacologyHuman papillomavirus vaccinationeducation.field_of_studyvaccine effectivenesshealthcare workersbusiness.industrylcsh:Rvaccinationmedicine.diseaseinfluenza vaccinationVaccinationEditorial030104 developmental biologyInfectious DiseasesFamily medicineHealthcare workervaccine hesitancymumpsHerpes zoster vaccinationbusinessVaccines
researchProduct

Interim 2017/18 influenza seasonal vaccine effectiveness: combined results from five European studies

2018

Between September 2017 and February 2018, influenza A(H1N1)pdm09, A(H3N2) and B viruses (mainly B/Yamagata, not included in 2017/18 trivalent vaccines) co-circulated in Europe. Interim results from five European studies indicate that, in all age groups, 2017/18 influenza vaccine effectiveness was 25 to 52% against any influenza, 55 to 68% against influenza A(H1N1)pdm09, -42 to 7% against influenza A(H3N2) and 36 to 54% against influenza B. 2017/18 influenza vaccine should be promoted where influenza still circulates. Funding: The five studies have received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 634446 to conduct the study in…

0301 basic medicineMalePediatricsEpidemiologyvirusesInfluenza B viruinfluenza ; influenza vaccine effectiveness ; influenza vaccination ; case control study ; multicentre study ; EuropeEurope case control study influenza influenza vaccination influenza vaccine effectiveness multicentre study0302 clinical medicineInfluenza A Virus H1N1 Subtype[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesInteriminfluenza vaccine effectivenessEpidemiologyPandemicInfluenza A Virus030212 general & internal medicineQAInfluenza vaccine effectivenessChildmedia_commonVaccine EffectivenessVaccinationvirus diseasesMiddle Agedinfluenza vaccinationmulticentre study3. Good healthVaccinationEuropeTreatment OutcomeInfluenza VaccinesChild PreschoolH3N2 SubtypeFemaleSeasonsInfluenza VaccineinfluenzaRapid CommunicationHumanAdultRMmedicine.medical_specialtyAdolescentInfluenza vaccine030106 microbiologyCase control studyMulticentre studyEuropean studiesSettore MED/07 - MICROBIOLOGIA E MICROBIOLOGIA CLINICA03 medical and health sciencesVirologyInfluenza Humanmedicinemedia_common.cataloged_instanceHumansH1N1 SubtypeVacina AntigripalEuropean UnionEuropean unionPreschoolPandemicsAgedPandemicInfluenza A Virus H3N2 SubtypeCuidados de SaúdePublic Health Environmental and Occupational HealthInfant NewbornInfantInfluenza ainfluenza vaccine effectivenecase control studyNewbornEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre studyInfluenzarespiratory tract diseasesInfluenza vaccinationInfluenza B virusEurope; case control study; influenza; influenza vaccination; influenza vaccine effectiveness; multicentre study; Adolescent; Adult; Aged; Child; Child Preschool; Europe; European Union; Female; Humans; Infant; Infant Newborn; Influenza A Virus H1N1 Subtype; Influenza A Virus H3N2 Subtype; Influenza B virus; Influenza Vaccines; Influenza Human; Male; Middle Aged; Pandemics; Treatment Outcome; Vaccination; Seasons[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologieDeterminantes da Saúde e da Doença[SDV.IMM.VAC]Life Sciences [q-bio]/Immunology/Vaccinology
researchProduct

Effectiveness of mRNA COVID-19 Vaccination on SARS-CoV-2 Infection and COVID-19 in Sicily over an Eight-Month Period

2022

In order to reduce the spread of SARS-CoV-2 infection and the burden of disease, since 27 December 2020, Sicily has introduced a regional COVID-19 vaccination campaign. This study aimed at estimating the effectiveness of mRNA COVID-19 vaccines on SARS-CoV-2 infections and COVID-19. A retrospective cohort study was carried out on 3,966,976 Sicilian adults aged 18 years or more, who were followed-up from 1 January 2021 to 30 September 2021. The risk of SARS-CoV-2 infection, severe COVID-19, and COVID-19 death or intubation during the study period was compared among vaccinated with two mRNA doses and unvaccinated individuals. Cox regression, adjusted for age and sex, and a joint-point analysis…

PharmacologyCOVID-19; vaccine effectiveness; mRNA vaccinesInfectious DiseasesmRNA vaccineDrug DiscoveryImmunologyCOVID-19Pharmacology (medical)vaccine effectiveness.
researchProduct